Alkermes (8AK) Stock Overview

A biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. More details

8AK fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	4/6
Past Performance	2/6
Financial Health	2/6
Dividends	0/6

Rewards

Trading at 48.4% below our estimate of its fair value

Earnings are forecast to grow 42.53% per year

Risk Analysis

Debt is not well covered by operating cash flow

Shares are highly illiquid

Profit margins (9.8%) are lower than last year (23.5%)

8AK Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Alkermes plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Alkermes
Historical stock prices
Current Share Price	US$46.22
52 Week High	US$46.22
52 Week Low	US$37.50
Beta	0.33
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	21.68%

Recent updates

Shareholder Returns

	8AK	DE Biotechs	DE Market
7D	23.0%	-0.6%	-0.8%
1Y	n/a	-7.8%	2.2%

Return vs Industry: Insufficient data to determine how 8AK performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 8AK performed against the German Market.

Price Volatility

Is 8AK's price volatile compared to industry and market?
8AK volatility
8AK Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.3%
Market Average Movement	5.7%
10% most volatile stocks in DE Market	13.2%
10% least volatile stocks in DE Market	2.8%

Stable Share Price: 8AK's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 8AK's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1987	2,050	Richard Pops	www.alkermes.com

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients.

Alkermes plc Fundamentals Summary

How do Alkermes's earnings and revenue compare to its market cap?
8AK fundamental statistics
Market cap	€7.40b
Earnings (TTM)	€134.32m
Revenue (TTM)	€1.37b

57.7x

P/E Ratio

5.6x

P/S Ratio

Is 8AK overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
8AK income statement (TTM)
Revenue	US$1.56b
Cost of Revenue	US$196.11m
Gross Profit	US$1.37b
Other Expenses	US$1.21b
Earnings	US$152.72m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	0.92
Gross Margin	87.45%
Net Profit Margin	9.78%
Debt/Equity Ratio	86.2%

How did 8AK perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/25 19:26
End of Day Share Price	2026/06/25 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alkermes plc is covered by 33 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	Baird
Joel Beatty	Baird
Luke Herrmann	Baird

Alkermes plcXTRA:8AK Stock Report